Difference between revisions of "Ziv-aflibercept (Zaltrap)"
Line 1: | Line 1: | ||
− | |||
− | |||
==General information== | ==General information== | ||
Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.<ref name="insert">[http://www.regeneron.com/zaltrap/zaltrap-fpi.pdf Ziv-aflibercept (Zaltrap) package insert]</ref><ref>[[Media:Zivaflibercept.pdf|Ziv-aflibercept (Zaltrap) package insert (locally hosted backup)]]</ref><ref>[http://www.regeneron.com/zaltrap/ Zaltrap manufacturer's website]</ref> | Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.<ref name="insert">[http://www.regeneron.com/zaltrap/zaltrap-fpi.pdf Ziv-aflibercept (Zaltrap) package insert]</ref><ref>[[Media:Zivaflibercept.pdf|Ziv-aflibercept (Zaltrap) package insert (locally hosted backup)]]</ref><ref>[http://www.regeneron.com/zaltrap/ Zaltrap manufacturer's website]</ref> | ||
Line 16: | Line 14: | ||
==Patient drug information== | ==Patient drug information== | ||
− | *Brief patient counseling information is available | + | *Brief patient counseling information is available in the [http://www.regeneron.com/zaltrap/zaltrap-fpi.pdf Ziv-aflibercept (Zaltrap) package insert].<ref name="insert"></ref> |
− | *[http://www.uptodate.com/contents/aflibercept- | + | *[http://www.uptodate.com/contents/aflibercept-ziv-aflibercept-systemic-drug-information Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/aflibercept-ziv-aflibercept-systemic-drug-information Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)]</ref> |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 8/31/2012: Initial FDA approval "in combination with [[Fluorouracil (5-FU) | 5-fluorouracil]], [[Folinic acid (Leucovorin) | leucovorin]], [[Irinotecan (Camptosar) | irinotecan]] - ([[Colon_cancer#FOLFIRI_.26_Ziv-aflibercept_.28Zaltrap.29 | FOLFIRI]]), is indicated for patients with [[Colon_cancer#Advanced_or_metastatic_disease | metastatic colorectal cancer (mCRC)]] that is resistant to or has progressed following an [[Oxaliplatin (Eloxatin) | oxaliplatin]]-containing regimen." | * 8/31/2012: Initial FDA approval "in combination with [[Fluorouracil (5-FU) | 5-fluorouracil]], [[Folinic acid (Leucovorin) | leucovorin]], [[Irinotecan (Camptosar) | irinotecan]] - ([[Colon_cancer#FOLFIRI_.26_Ziv-aflibercept_.28Zaltrap.29 | FOLFIRI]]), is indicated for patients with [[Colon_cancer#Advanced_or_metastatic_disease | metastatic colorectal cancer (mCRC)]] that is resistant to or has progressed following an [[Oxaliplatin (Eloxatin) | oxaliplatin]]-containing regimen." | ||
+ | |||
+ | ==Also known as== | ||
+ | aflibercept, Eylea, VEGF trap | ||
==References== | ==References== |
Revision as of 08:15, 2 March 2015
General information
Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Clinical trials
- VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)[4]
Patient drug information
- Brief patient counseling information is available in the Ziv-aflibercept (Zaltrap) package insert.[1]
- Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 8/31/2012: Initial FDA approval "in combination with 5-fluorouracil, leucovorin, irinotecan - ( FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen."
Also known as
aflibercept, Eylea, VEGF trap
References
- ↑ 1.0 1.1 1.2 Ziv-aflibercept (Zaltrap) package insert
- ↑ Ziv-aflibercept (Zaltrap) package insert (locally hosted backup)
- ↑ Zaltrap manufacturer's website
- ↑ J. Tabernero, E. Van Cutsem, R. Lakomy, J. Prausova, P. Ruff, G. Van Hazel, V. Moiseyenko, D. Ferry, J. McKendrick, K. Soussan-Lazard, E. Boelle, C. Allegra. VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC). 2011 European Multidisciplinary Congress. Abstract 6LBA. Presented September 25, 2011.
- ↑ Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)